Intellia Therapeutics, Inc. (NTLA) Stock Forecast & Price Prediction 2025, 2030, 2040, and 2050
Find Intellia Therapeutics, Inc. (NTLA) short-term stock forecasts for 2025 by month and long-term price predictions for 2025 to 2050. View past performance, analyst Buy, Sell or Hold ratings, and the latest NTLA stock news and headlines.
1 Month Prediction
$30.00 [229.89%]
3 Month Prediction
$28.09 [208.86%]
6 Month Prediction
$22.98 [152.67%]
1 Year Prediction
$6.56 [-27.86%]
3 Year Prediction
$1.00 [-89.00%]
5 Year Prediction
$1.00 [-89.00%]
About Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. is a biotechnology company that uses CRISPR/Cas9 gene-editing technology to develop potentially curative treatments for severe diseases. The company focuses on conditions like liver diseases, immuno-oncology, and autoimmune disorders. Their key pipeline products include NTLA-2002 for hereditary angioedema and nexiguran ziclumeran (nex-z) for transthyretin amyloidosis.
The company was founded in 2014, and is headquartered in Cambridge, Massachusetts.
Intellia Therapeutics, Inc. (NTLA) Historical Performance
IPO Date
Intellia Therapeutics, Inc. (NASDAQ:NTLA) went public on 05 June, 2016.
Change
Since inception, NTLA has decreased by 69.24%. In the last 5 years, NTLA has fallen from $13.47 to $9.10, a massive -32.48% decrease since 2020.
Historical Highs and Lows
In the past 5 years, the stock reached a high of $161.91 and a low of $9.10.
52 Week Range
$8.3
$32.0
The current price $9.10 is near the 52-week low, which means that the stock is underbought.
NTLA Stock Price History
Based on NTLA stock's historical price data, this table shows how the stock has performed in the last 6 years. Since 2019, the NTLA stock has fallen from $11.91 - $54.4 to $9.1 - $10.32, which is down -34.76%. Currently, the stock follows downward trend.
Here, we have calculated stock range of NTLA, indicating the highs and lows for each year, the average price based on the daily closing prices each year, and the change% from the average price.
| Year | Stock Price | Avg Price | Change% | Year Change |
|---|---|---|---|---|
| 2020 | $11.91 - $54.4 | $22.2 | 47.18 | 1 Year Change |
| 2021 | $60.46 - $161.91 | $109.98 | 629.12 | 2 Year Change |
| 2022 | $34.89 - $98.85 | $61.08 | 304.94 | 3 Year Change |
| 2023 | $25.05 - $42.44 | $36.02 | 138.8 | 4 Year Change |
| 2024 | $11.66 - $32.12 | $21.61 | 43.27 | 5 Year Change |
| 2025 | $9.1 - $10.32 | $9.84 | -34.76 | 6 Year Change |
NTLA Price Performance
6-Month Performance
NTLA stock dropped by 36.04% in the last six months.
1-Year Performance
The stock has trended downwards by 57.50% in the past year.
3-Year Performance
In the last 3 years, the stock has plummeted by 81.45%.
5-Year Performance
In the last 5 years, the stock has gone down by 32.48%.
According to Intellia Therapeutics, Inc.'s historical data, below graph gives us the exact picture of how the NTLA stock has performed year-over-year. Here, Each bar on the graph represents a particular year that illustrates how the stock's price changed from one year to the next.
YoY Performance
In the last five years, the stock has shown positive growth in 2 years and a decline in 3 years.
2020
270.82% ↑
2021
117.35% ↑
2022
70.49% ↓
2023
12.61% ↓
2024
61.76% ↓
NOTE: Green bars indicate that the stock has risen compared to the previous year, while red bars show that the stock has fallen.
Intellia Therapeutics, Inc. (NTLA) Financials & Stock Analysis
Total Revenue
Quarterly Revenue: $12.87 M (Q4)
Revenue for Q4 ending 31st December, 2024 increased 41.30% compared to Q3 ending 30th September, 2024.
Annual Revenue: $57.88 M (1Y)
Revenue for trailing 12 months decreased 0.00% year over year from 31st December, 2024.
If compared to the last 4 years, the revenue has gone up from $33.05 million to $57.88 million, a 75.10% change.
Market Capitalization
Intellia Therapeutics, Inc. has a market capitalization of $941.49M, which places NTLA in the small-cap category.
Fundamental Analysis
EPS: $nan (Q4), $-5.25 (1Y)
EPS decreased nan% since last quarter, and decreased 3.14% since last year.
Net Income: $-128.90 M (Q4), $-519.02 M (1Y)
Net Income decreased 5.02% since last quarter, and increased 7.86% since last year.
Free Cash Flow: $-86.18 M (Q4), $-354.66 M (1Y)
Free Cash Flow increased 0.07% since last quarter, and decreased 13.09% since last year.
Net Profit Margin: -1001.23% (Q4), -896.77% (1Y)
Net Profit Margin decreased 32.78% since last quarter, and increased 7.86% since last year.
Below, we have listed 12 key indicators for Fundamental analysis for NTLA stock. These indicators help you understand Intellia Therapeutics, Inc.'s financial health, earnings and growth potential, and make a decision if the stock is a good long-term investment or not.
|
|
Technical Analysis
Here, we have listed 5 key indicators for Technical Analysis for NTLA stock. These indicators help investors study past price movements and trading volumes to forecast future price changes, and find the right time when to buy, sell or hold the stock.
| Technical Indicators | Value |
|---|---|
| SMA20 | $10.47 |
| SMA50 | $10.83 |
| SMA200 | $18.29 |
| RSI | 49.12 |
| Beta | 1.97 |
SMA20 > Current Price
This signals NTLA stock is in short-term bearish momentum.
SMA50 > Current Price
This signals NTLA stock is in mid-term bearish momentum.
SMA200 > Current Price
This signals NTLA stock is in long-term bearish momentum.
Sentiment Based on Technical Analysis
Based on 8 technical analysis indicators, the overall sentiment for NTLA stock is Bearish. Out of all indicators, 1 indicates bullish signals, 5 signals bearish trends and 3 gives neutral trends. The NTLA stock forecast was last updated on 05 March, 2025.
Intellia Therapeutics, Inc. (NTLA) Stock Price Prediction and Forecast
According to short-term forecast, the stock is expected to rise to $13.49 by the end of 2025, and can reach around $32.59 to $1.04 in 2026. And, the long-term forecast suggests that the stock may further drop to $0.81 - $0.87 in 2028, and $0.73 - $0.92 by 2031. So, the NTLA stock shows a strong upward trend in the next several years.
Short-term NTLA Stock Price Prediction & Forecast
| Date | Forecasted Price | Change% |
|---|---|---|
| 2025-04 | $30.00 | 229.85% |
| 2025-05 | $28.35 | 211.71% |
| 2025-06 | $28.09 | 208.85% |
| 2025-07 | $30.66 | 237.11% |
| 2025-08 | $25.78 | 183.45% |
| 2025-09 | $22.98 | 152.67% |
| 2025-10 | $10.46 | 15.01% |
| 2025-11 | $13.79 | 51.62% |
| 2025-12 | $13.49 | 48.32% |
In 2025, the NTLA stock price is expected to fluctuate between $10.46 and $30.66. According to the monthly forecast, the stock could rise to $13.49 by December 2024. If compared to the NTLA's current price, the stock could gain 48.32% by the end of this year.
Long-term NTLA Stock Price Prediction & Forecast
| Year | Year Start | Year Mid | Year End | Change% |
|---|---|---|---|---|
| 2026 | $32.59 | $7.99 | $1.04 | -88.57% |
| 2027 | $0.74 | $1.03 | $1.03 | -88.68% |
| 2028 | $0.81 | $1.16 | $0.87 | -90.43% |
| 2029 | $0.90 | $0.86 | $0.97 | -89.33% |
| 2030 | $0.90 | $0.70 | $1.08 | -88.13% |
| 2031 | $0.73 | $0.92 | $0.92 | -89.88% |
| 2032 | $0.69 | $0.80 | $1.21 | -86.7% |
| 2033 | $0.97 | $1.32 | $0.95 | -89.55% |
| 2034 | $1.33 | $0.99 | $1.36 | -85.05% |
| 2035 | $1.16 | $0.87 | $1.19 | -86.92% |
| 2036 | $1.11 | $0.96 | $0.96 | -89.44% |
| 2037 | $1.07 | $0.83 | $0.87 | -90.43% |
| 2038 | $1.03 | $1.13 | $0.97 | -89.33% |
| 2039 | $0.91 | $0.91 | $1.04 | -88.57% |
| 2040 | $1.08 | $1.18 | $1.06 | -88.35% |
| 2041 | $0.92 | $1.25 | $1.13 | -87.58% |
| 2042 | $0.94 | $1.11 | $0.88 | -90.32% |
| 2043 | $1.10 | $0.98 | $1.07 | -88.24% |
| 2044 | $1.04 | $0.89 | $0.76 | -91.64% |
| 2045 | $0.98 | $0.91 | $0.93 | -89.77% |
| 2046 | $1.00 | $1.06 | $1.15 | -87.36% |
| 2047 | $1.03 | $1.05 | $0.87 | -90.43% |
| 2048 | $0.73 | $0.95 | $0.97 | -89.33% |
| 2049 | $0.86 | $1.17 | $1.09 | -88.02% |
| 2050 | $0.92 | $0.96 | $0.82 | -90.98% |
| 2051 | $1.16 | $0.76 | $1.01 | -88.89% |
Intellia Therapeutics, Inc. (NTLA) Stock Price Prediction & Forecast 2025
At the start of 2025, the NTLA stock was at $10.32. Today, it is trading at $9.10, which is -11.87% decrease from price at the beginning of the year. By the end of this year, you can expect the stock to reach to $13.49 by December 2025 with a 48.32% change.
Intellia Therapeutics, Inc. (NTLA) Stock Price Prediction & Forecast 2026 - 2030
In the next five years, there will be a significant depreciation in the NTLA stock. During this period, the NTLA's price is forecasted to shift from $32.59 to $1.08, which is -96.69% loss.
In 2026, the stock would possibly open at $32.59, descends to $7.99 by mid-year, and wraps up at $1.04, reflecting a decrease from today's price. Further moving to 2030, the stock can kick off the year at $0.90, drop to $0.70 by mid-year, and finish at $1.08, which is -88.14% change from current price.
Intellia Therapeutics, Inc. (NTLA) Stock Price Prediction & Forecast 2031 - 2040
During this period, the stock would move from $0.73 to $1.06, which is up -89.85%
In 2031, we can expect NTLA to fluctuate between $0.73 and $0.92, a shift indicating a -89.85% loss by year-end compared to current price. And Until 2040, NTLA can likely vary from $1.06 to $1.08. By the end of 2040, the stock could record a -88.38% fall from today's stock price.
Intellia Therapeutics, Inc. (NTLA) Stock Price Prediction & Forecast 2041 - 2050
According to long-term forecast, the NTLA stock can see an a downturn from $0.92 to $0.82 in this period. In 2041, the stock can experience a high of $1.25 by mid-year, closing the year at $1.13. This results in a -86.26% decrease from today.
Moving towards the end of 2050, NTLA is projected to open the year at $0.92. The stock may peak to $0.96 during mid-year and finish the year at $0.82. Compared to the stock's current price, this translates to an overall loss of -90.94% by 2050.
Become a member
Get the latest news right in your inbox. We never spam!
NTLA Competitors
| Ticker | Company | Market Cap | Price | 1m Change | Forecast |
|---|---|---|---|---|---|
| TNYA | Tenaya Therapeutics, Inc. | - | $0.46 | -54.95% ▼ | $790.53 ▲ |
| MRSN | Mersana Therapeutics, Inc. | - | $0.54 | 4.07% ▲ | $519.39 ▲ |
| XERS | Xeris Biopharma Holdings, Inc. | - | $4.13 | 7.83% ▲ | $41.7 ▲ |
| PSTV | Plus Therapeutics, Inc. | - | $1.44 | 97.26% ▲ | $70.11 ▲ |
| ONVO | Organovo Holdings, Inc. | - | $1.27 | 252.78% ▲ | -3.29 ▼ |
Last updated Mar 05 at 9:02 AM
NTLA : Buy, Sell Or Hold?
Analyst Ratings
Based on 25 analysts, 2 rated as a strong buy, 16 recommended a buy, 6 suggested a hold, 0 advised a sell, and 1 indicated a strong sell.Three months ago, out of 26 analysts, 5 analysts gave a strong buy rating, 16 a buy rating, 5 a hold rating, 0 advised selling, and 0 suggested a strong sell.So, according to analyst ratings, the recommendation for NTLA stock is Buy.
Expert Analysis
According to NTLA short-term and long-term forecast, Intellia Therapeutics, Inc. shares are projected to go down by 90.98%, and reach a value of $0.82 per share by 2050.
As per technical analysis, indicators show a Bearish sentiment, while Fear & Greed Index stands at 42.857142857142854, which signals Fear. Also, NTLA has recorded 8/30 green days, which reflects a 38.095238095238095% positivity rate with a price volatility of 0.05%.
Plus, Price-to-Earnings (P/E) ratio of 0 suggests that NTLA stock is undervalued. So, Based on NTLA prediction and analysis, it may be the best time to sell NTLA stock right now.
Disclaimer: Stock predictions, forecasts and price targets provided for "NTLA” are solely for informational and educational purposes and should not be treated as investment or financial advice. Always conduct your own research or consider consulting with a financial advisor before making any investment decisions.